Olmesartán/Amlodipino Tecnigen (Olmesartan Medoxomil, Amlodipine)

Olmesartán/Amlodipino Tecnigen is used in the management of hypertension, acting on the renin‑angiotensin system and vascular smooth muscle tone.

• Essential hypertension: lowers systolic and diastolic blood pressure to help patients reach guideline‑recommended targets.
• Hypertension with cardiovascular risk: provides combined ARB and calcium‑channel blockade for enhanced blood pressure control.
• Uncontrolled hypertension on monotherapy: adds additive antihypertensive effect when a single agent is insufficient.
• Isolated systolic hypertension: reduces elevated systolic pressure in elderly patients.
• Hypertension in patients with diabetes: offers renal protective benefits alongside blood pressure reduction.

• Olmesartan medoxomil is an angiotensin II receptor blocker that selectively antagonizes the AT₁ receptor, preventing angiotensin II‑mediated vasoconstriction, aldosterone secretion, and sympathetic activation. Amlodipine is a dihydropyridine calcium‑channel blocker that inhibits L‑type calcium channels in arterial smooth muscle, causing dose‑dependent vasodilation. The fixed‑dose combination therefore reduces peripheral vascular resistance through two complementary mechanisms, resulting in a synergistic decrease in systemic blood pressure.

Adverse reactions reported with the Olmesartan/Amlodipine combination include both common and less frequent events.

Common Side Effects

• Dizziness: sensation of light‑headedness, especially after standing.
• Headache: mild to moderate pressure in the head.
• Peripheral edema: swelling of ankles or lower legs.
• Flushing: transient warmth and redness of the skin.
• Fatigue: feeling of tiredness or lack of energy.
• Palpitations: awareness of heartbeat irregularities.

Serious or Rare Side Effects

• Angioedema: rapid swelling of face, lips, tongue, or airway.
• Severe hypotension: marked drop in blood pressure causing faintness.
• Hepatic enzyme elevation: increased ALT/AST indicating liver stress.
• Myocardial infarction: acute heart attack symptoms.
• Arrhythmias: abnormal heart rhythms that may require medical attention.
• Acute kidney injury: sudden decline in renal function.

When prescribing Olmesartan/Amlodipine, clinicians should consider several precautionary measures to ensure patient safety.

• Renal function monitoring: assess serum creatinine and eGFR before and during therapy.
• Electrolyte balance: check potassium levels, especially when combined with potassium‑sparing agents.
• Hepatic impairment: use with caution in patients with liver disease; monitor liver enzymes.
• Pregnancy: contraindicated; avoid use in women who are pregnant or may become pregnant.
• Elderly patients: start at lower dose and monitor for hypotension and dizziness.
• Store at room temperature: keep tablets in the original container, protect from moisture and direct sunlight.

Olmesartan/Amlodipine may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• ACE inhibitors or other ARBs: combined use can increase risk of hyperkalemia and renal dysfunction.
• Aliskiren in diabetic patients: may cause renal impairment and hyperkalemia.
• Potassium‑sparing diuretics: additive effect on serum potassium leading to hyperkalemia.
• NSAIDs: can reduce antihypertensive effect and impair renal function.

Moderate Interactions (Monitor Closely)

• CYP3A4 inhibitors (e.g., diltiazem, ketoconazole): may raise amlodipine concentrations, increasing risk of edema and hypotension.
• CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower amlodipine levels, reducing efficacy.
• Diuretics: concurrent use may enhance blood pressure lowering, requiring dose adjustment.
• Lithium: ARBs can increase lithium levels, risking toxicity.
• Other antihypertensives: additive blood pressure reduction may cause symptomatic hypotension.